Modifying PEST for Psoriatic Arthritis Screening
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorNovartis Pharmaceuticals
About this trial
The purpose of this study is to assess the impact of adding two questions and pictures to the validated PEST on the potential diagnosis of PsA in participants with moderate-to-severe plaque PsO in Canada.
Eligibility criteria
Qualifiers
Moderate-to-severe plaque PsO patients who are candidates for bDMARDs, according to physician's clinical judgement at the time of patient enrollment.
Adult patients at the time of informed consent signature
Patients able to understand and willing to comply with protocol requirements, instructions, and restrictions
Residents of Canada
Disqualifiers
Patients who have previously screened positive for PsA through PEST.
Patients who have been diagnosed with PsA.
Patients who have been diagnosed with inflammatory arthritis unrelated to PsA (rheumatoid arthritis, reactive arthritis, enteropathic arthritis, axial spondyloarthritis)
Patients treated with a bDMARD for moderate-to-severe plaque PsO or any other medical condition within the last 6 months prior to patient enrollment.
Trial design
Treatments tested in this trial
- PEST Screening group
Treatment groups
502 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov